VolitionRx Limited (VNRX) AI Stock Analysis

VolitionRx Limited, headquartered in Austin, Texas, is an epigenetics company focused on developing blood tests to diagnose various cancers and other diseases globally. Its primary diagnostic products include Nu.Q for human cancer detection, Nu.Q Nets for monitoring immune dynamics, and Nu.Q Vet for veterinary cancer screening. The company relies on its proprietary Nucleosomics technology platform, which underpins its testing portfolio. This platform includes Nu.Q Capture for sample isolation and concentration, as well as Nu.Q Discover for nucleosome profiling to evaluate disease biomarkers.

VolitionRx increased annual revenue from $90,035 in FY2021 to $306,392 in FY2022, $775,302 in FY2023, $1.2M in FY2024, and $1.7M in FY2025, achieving a 5-year revenue CAGR of 164.1%. Gross margin was reported at 100.0% in each fiscal year from FY2021 to FY2025. However, operating losses remained substantial, with FY2025 operating margin at -1228.6% and a net income of -$23.4M. For the trailing twelve months, revenue was $2.5M with an operating margin of -1042.5% and EPS of -$3.80. In the quarter ended June 30, 2026, revenue fell 2.0% year-over-year.

As of June 30, 2026, VolitionRx held $2.8M in cash and short-term investments alongside total debt of $12.0M, resulting in net debt of $9.2M and negative shareholders' equity of -$32.2M. Total assets were $8.3M, and the current ratio stood at 0.30. In FY2025, operating cash flow was -$19.7M, free cash flow was -$19.8M, and capital expenditures were $89,558. The company's share count increased 244.4% over a 5-year span.

VolitionRx carries a market capitalization of $5.4M and an enterprise value of $15.5M. The stock trades at a price-to-sales multiple of 2.2x, below the 4.1x median of its US-listed Healthcare peers. Its forward P/E stands at 20.8x compared to the peer median of 17.3x, while its EV-to-revenue ratio is 6.3x. Over the past year, the stock fell 98.0%, trailing the 16.8% return of the S&P 500. Over 5 years, the stock dropped 99.7%, while the benchmark gained 83.0%.

Wall Street coverage includes 3 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $13.62, compared to the last close of $0.18 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate revenue of $2.7M and EPS of -$2.00. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of VolitionRx Limited (VNRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VNRX income statement, VNRX balance sheet, VNRX key metrics, VNRX analyst forecast, VNRX chart. See the VNRX stock overview for the latest quote and news.